Vertex(VRTX) - 2025 Q1 - Quarterly Results

Vertex Reports First Quarter 2025 Financial Results — Total revenue of $2.77 billion, a 3$100 million to a new range of $11.85 to$12 billion — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, a ...